迪瑞医疗
(300396)
| 流通市值：64.47亿 | | | 总市值：68.23亿 |
| 流通股本：2.59亿 | | | 总股本：2.75亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 662,535,125.59 | 1,378,059,471.02 | 1,048,603,608.02 | 694,934,022.13 |
| 营业收入 | 662,535,125.59 | 1,378,059,471.02 | 1,048,603,608.02 | 694,934,022.13 |
| 二、营业总成本 | 532,151,957.58 | 1,121,427,051.03 | 834,307,086.89 | 546,154,271.23 |
| 营业成本 | 421,381,170.19 | 681,683,965.68 | 525,892,711.96 | 350,679,301.84 |
| 税金及附加 | 3,509,850.5 | 14,739,230.32 | 9,426,128.11 | 6,277,819.39 |
| 销售费用 | 61,548,750.18 | 250,457,300.16 | 158,243,811.97 | 103,991,327.5 |
| 管理费用 | 12,424,634.92 | 58,271,116.38 | 51,569,811.75 | 32,110,463.73 |
| 研发费用 | 32,040,993.06 | 128,625,580.07 | 85,343,396.06 | 51,193,559.8 |
| 财务费用 | 1,246,558.73 | -12,350,141.58 | 3,831,227.04 | 1,901,798.97 |
| 其中:利息费用 | 1,893,526.4 | 8,794,982.13 | 6,383,397.43 | 4,199,396.82 |
| 其中:利息收入 | 2,110,974.15 | 29,536,567.62 | 12,264,855.35 | 5,305,984.69 |
| 加:公允价值变动收益 | -327,531.63 | 775,318.94 | -270,951.35 | -590,953.41 |
| 加:投资收益 | 6,240,842.95 | 32,715,471.72 | 26,911,000.18 | 18,394,505.51 |
| 资产处置收益 | 0 | 469.71 | 469.71 | 469.71 |
| 资产减值损失(新) | 311,476.51 | -9,053,088.69 | -102,370.55 | -73,842.39 |
| 信用减值损失(新) | -9,436,027.29 | -9,633,991.03 | -2,375,817.08 | -1,094,522.35 |
| 其他收益 | 14,239,074.57 | 25,437,561.99 | 17,964,894.14 | 13,740,485.67 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 141,411,003.12 | 296,874,162.63 | 256,423,746.18 | 179,155,893.64 |
| 加:营业外收入 | 114,046.11 | 1,318,119.75 | 390,244.53 | 283,907.33 |
| 减:营业外支出 | 537,206.44 | 1,996,142.07 | 857,477.66 | 416,039.82 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 140,987,842.79 | 296,196,140.31 | 255,956,513.05 | 179,023,761.15 |
| 减:所得税费用 | 19,194,365.68 | 20,624,164.43 | 21,689,706.86 | 17,216,052.71 |
| 六、净利润 | 121,793,477.11 | 275,571,975.88 | 234,266,806.19 | 161,807,708.44 |
| 持续经营净利润 | 121,793,477.11 | 275,571,975.88 | 234,266,806.19 | 161,807,708.44 |
| 归属于母公司股东的净利润 | 121,800,597.55 | 275,589,641.99 | 234,282,503.69 | 161,817,683.71 |
| 少数股东损益 | -7,120.44 | -17,666.11 | -15,697.5 | -9,975.27 |
| (一)基本每股收益 | 0.45 | 1.01 | 0.86 | 0.59 |
| (二)稀释每股收益 | 0.45 | 1.01 | 0.86 | 0.59 |
| 八、其他综合收益 | 542,085.22 | -40,131,295.45 | -2,382,821.48 | -639,833.45 |
| 归属于母公司股东的其他综合收益 | 543,571.52 | -40,132,327.79 | -2,382,481.49 | -640,253.76 |
| 九、综合收益总额 | 122,335,562.33 | 235,440,680.43 | 231,883,984.71 | 161,167,874.99 |
| 归属于母公司股东的综合收益总额 | 122,344,169.07 | 235,457,314.2 | 231,900,022.2 | 161,177,429.95 |
| 归属于少数股东的综合收益总额 | -8,606.74 | -16,633.77 | -16,037.49 | -9,554.96 |
| 公告日期 | 2024-04-19 | 2024-04-19 | 2023-10-25 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |